DNTH

Dianthus Therapeutics, Inc.

Fundamental data last updated:October 20, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

 


Analyze DNTH on TradingView

VALUATION

P/E

-385.43

Market Cap ($M USD)

$3.79B

Forward P/E

39.15

PEG

0.04

PRICE TO SALES

2839.38

PRICE TO BOOK

3.63

EV / EBITDA

-16.90

5-Year Average P/E

Free Cash Flow Yield

-3.44%

DCF Value

$-2.93

Graham Number

N/A

Price to FCF

-29.07

EV to FCF

-24.27

Earnings Yield

-0.26%

FCF Yield

-3.44%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.24

Next Year EPS Growth Estimate

$2.32

Next Year Revenue Growth Estimate

$618.26M

Return on Equity (ROE)

-1.78%

FREE CASH FLOW

Operating Margin

-14318.04%

Debt-to-Equity

0.00

Piotroski F-Score

1

Altman Z-Score

47.76

Return on Invested Capital (ROIC)

-15.83%

Current Ratio

29.25

Quick Ratio

29.25

Net Debt to EBITDA

3.34

Interest Coverage

0.00

Gross Profit margin

94.31%

FCF PER SHARE

$-2.72

REVENUE PER SHARE

$0.03

Analyze DNTH on TradingView

Gainseekers Quantitative Analysis

Summary

The market appears to be mispricing Dianthus Therapeutics, Inc. significantly. Despite a staggering negative DCF value, the stock has traded well above this, suggesting a disconnect between intrinsic value and market perception. The Forward P/E of 37.34 indicates optimism for future earnings, yet the current Earnings Yield is abysmally low, reflecting poor profitability. However, the Altman Z-score of 47.79 suggests financial stability, indicating the company is not at risk of bankruptcy. This juxtaposition of high growth expectations and current financial weakness paints a complex picture for investors.

AI Exposure / Tech Reliance

In the rapidly evolving biotechnology sector, Dianthus Therapeutics is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with modern tech shifts, potentially enhancing R&D efficiency. This adaptability could be a crucial factor in maintaining a competitive edge.

The Bull Case

For the value-driven investor, Dianthus offers intriguing potential. The Forward PEG ratio of 0.034 suggests the stock is undervalued relative to its growth prospects. Despite a low Piotroski F-Score, the company's robust Altman Z-score and high Current Ratio highlight its financial resilience. These metrics suggest that, while current profitability is lacking, the company has the capital efficiency and growth trajectory to potentially deliver substantial returns.

The Bear Case

Dianthus faces significant structural risks, particularly with its sky-high Price/Sales ratio of 2708.03 and negative cash flow metrics. The stock's proximity to its 52-week high raises concerns about technical overextension. Additionally, the negative ROIC and operating margins reflect severe inefficiencies in capital allocation and operational execution. These factors, combined with a negative Price to FCF, suggest that the stock may be overvalued and vulnerable to correction.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$111.91

Institutional Ownership %

1-Year Beta

0.09

Insider Buying % (6 Mo)

Distance to 52-Week High

6.21%

Distance to 52-Week Low

81.69%

EARNINGS SURPRISE %

27.35%

50-DAY SMA

$86.61

200-DAY SMA

$52.96

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.